ALB and hepatocellular carcinoma: Another proposed risk score for HCC patients receiving immunotherapy was the hepatocellular carcinoma immune prognosis score (HCIPS), which was developed using albumin and thrombin time from a retrospective single-center study from China, in 151 patients who received atezolizumab-bevacizumab or camrelizumab-apatinib at the context of a clinical trial (60).